Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H13N2O3.Na |
| Molecular Weight | 220.2009 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC1(CC)C(=O)[N-]C(=O)N(C)C1=O
InChI
InChIKey=RIJRFNRKNTXEGB-UHFFFAOYSA-M
InChI=1S/C9H14N2O3.Na/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13;/h4-5H2,1-3H3,(H,10,12,14);/q;+1/p-1
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/209272 |
10.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | GEMONIL Approved UseLong-acting barbiturate that is demethylated to barbital in the liver; has broad-spectrum anticonvulsant action, but used mainly to treat myoclonic spasms in infants. |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8638929/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8638929/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8638929/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8638929/ |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Monitoring antiepileptic drugs: a level-headed approach. | 2009-06 |
|
| A categorical structure-activity relationship analysis of the developmental toxicity of antithyroid drugs. | 2009 |
|
| Evaluation of pyridine-3-carboxylic acid as a drug carrier by utilizing multivariate methods, structure property correlations, and pattern recognition techniques. | 2004 |
|
| Effects of barbiturates on human platelet aggregation differ depending on their chemical structures. | 2003-08 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/13902356
Metharbital is administered orally. Effective dose, causing a reduction in seizure score by 225, is 110 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/209272
The binding of [3H]DHP (dihydropicrotoainin) to rat brain membrane fragments was measured by a centrifugation assay. Assay condition involved incubating 1-3 mg of protein at 0° for 15 min with 63 nM [3H]DHP with or without a given concentration of barbiturate in a total incubation medium of 2 ml. Following incubation, the vials were centrifuged, supernatant discarded, pellets rapidly rinsed, solubilized and prepared for counting as previously described (26) . Specific binding was obtained by subtracting from the total radioactivity in the pellet the background, i .e . the amount not displaced by high concentrations (0.1 mM) of unlabeled DHP. Metharbital inhibits binding of [3H]DHP to GABAA receptor with IC50 of 10 uM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
14148198
Created by
admin on Mon Mar 31 21:51:58 GMT 2025 , Edited by admin on Mon Mar 31 21:51:58 GMT 2025
|
PRIMARY | |||
|
359HKV5H10
Created by
admin on Mon Mar 31 21:51:58 GMT 2025 , Edited by admin on Mon Mar 31 21:51:58 GMT 2025
|
PRIMARY | |||
|
35107-70-1
Created by
admin on Mon Mar 31 21:51:58 GMT 2025 , Edited by admin on Mon Mar 31 21:51:58 GMT 2025
|
PRIMARY | |||
|
DTXSID50956543
Created by
admin on Mon Mar 31 21:51:58 GMT 2025 , Edited by admin on Mon Mar 31 21:51:58 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD